Background: It is well known that gastric mucosa dysplasia and intestinal metaplasia are gastric precancerous lesions (GPL).
Introduction
The typical pathological features of gastric precancerous lesions (GPL) are gastric mucosa dysplasia and intestinal metaplasia, which is closely associated with gastric carcinogenesis (Marques-Silva et al., 2014; Yoon and Kim, 2015) . Helicobacter pylori infection, dietary habits, immune factors and duodenal reflux were involved in the mechanism of GPL (Pan et al., 2014 United States), electrophoretic apparatus (Bio-Rad Laboratories, Inc., Hercules, California, USA), polymerase chain reaction system (Applied Biosystems co., Ltd., Waltham, MA, USA), electrophoresis groove (Beijing Donglin Changsheng biotechnology co., Ltd., Beijing, China).
Rat model of GPL
Model replication method was as follow: MNNG was mixed into the drinking water to arrive the final concentration of 150μg/ml. The bottle with MNNG solution was wrapped with aluminum foil in order to protect it from light. Rats drink the fresh prepared MNNG solution freely for each day. At the same time, rat's tail was clipped everyday. Last, irregular diet was carried out that rats got 2 days full feeding and 1 day no feeding recurrently. One rat was sacrificed every 2 weeks. The stomach section was stained with Hematoxylin and Eosin (HE) for routine pathological examination by light microscopy. Figure 1 shows the study design for moxibustion treatment of GPL rats. Sixty rats were randomly assigned to two groups:
Study design
Control group (n = 10) and Model replication group (n = 50). One rat of model replication group was sacrificed every 2 weeks to confirm the establishment of GPL model until the end of 20 th week, and 10 rats had used in total. The other 40 rats were further randomly divided into 4 subgroups: GPL group (n = 10), GPL+Moxa(ST) group (n = 10), GPL+Moxa(Sham) group (n = 10) and gastric precancerous lesions (GPL). Some of them were used to test whether the model was established successfully every 2 weeks. The other rats were divided into four groups: GPL rats without moxibustion treatment, GPL rats with moxibustion treatment on ST21 and ST36, GPL rats with moxibustion treatment on Sham, and GPL rats with vitacoenzyme treatment. The whole treatment course lasted for 20 weeks and then evaluated their effect.
Moxibustion treatment
In the GPL+Moxa(ST) group, moxibustion was applied at ST21 and ST36, located according to the textbook "Experimental Acupuncture & Moxibustion" (Li, 2003) . ST21 was located at the intersection of midclavicular line and horizontal line of 3/4 distance from the upper edge of the sternum to the external genital organs. ST36 was located ~5mm below the capitulum fibulae.
In the GPL+Moxa(Sham) group, moxibustion was applied at 1cm lateral to ST21 and 1cm medial to ST36 ( Figure S1 ). Rats in the GPL+Moxa(ST) and GPL+Moxa(Sham) groups were treated unilaterally with lit moxa respectively, from the second day of model replication. Prior to treatment, rats were fixed on boards and hair was clipped around the site of stimulations. Cottons with isoflurane were put into 50ml tubes, and rats inhaled isoflurane during moxibustion treatment. Lit moxa cones (width 1.75cm) were fixed using self-made moxibustion equipment to ensure the lit ends were 0.5cm away from the surface of the skin.
Moxibustion was applied for 15 minutes every other day for 20 weeks in total and laterality was alternated with each session.
the routine tissue slice of gastric mucosal tissue stained by HE from five groups and observed by light microscopy. At 12 weeks, the stomach of model replication group represents less gastric mucosal folds than that of control group, HE staining of the stomach showed gastric mucosal glands atrophy and decrease ( Figure S2 ). At 20 weeks, the structure of the gastric mucosa in Control rats was intact and visible lesions were not evident microscopically. However, in untreated GPL rats, the structure of gastric mucosa was incomplete, irregular glands and divided cellular nuclei were evident under high magnification. Both moxibustion at ST21 and ST36 and vitacoenzyme treatment appeared to attenuate the severity of gastric mucosal lesions, because the arrangement of the gastric gland was more regular and glandular atrophy was not observed. By contrast, moxibustion at Sham points did not appear to protect the gastric mucosa from pathological lesions (Figure 2 
Effect of moxibustion treatment on cell apoptosis-related proteins
To explore the mechanism of moxibustion treatment on gastric precancerous lesions in vivo, we further study the cell apoptosis-related proteins by using RT-PCR. As shown in Figure 3 , the mRNA expression of bcl-2, P53 and C-MYC in gastric mucosa of GPL group was significantly up-regulated when compared with the healthy Control group (2.95 ± 0.14 vs 2.18 ± 0.13, 0.79 ± 0.05 vs 0.35 ± 0.03, 0.72 ± 0.10 vs 0.18 ± 0.01, respectively, P < 0.01). Moxibustion treatment at ST21 and ST36 significantly down-regulated the expression of bcl-2, p53 and C-MYC in GPL rats relative to no treatment (1.18 ± 0.07 vs 2.95 ± 0.14, 0.40 ± 0.05 vs 0.79 ± 0.05, 0.39 ± 0.03 vs 0.72 ± 0.10, respectively, P < 0.01), which was lower than that of moxibustion treatment at Sham points (1.18 ± 0.07 vs 2.73 ± 0.15, 0.40 ± 0.05 vs 0.79 ± 0.07, respectively, P < 0.01, and 0.40 ± 0.03 vs 0.52 ± 0.08, P < 0.05). And drug treatment also showed the similar down-regulating effect on the mRNA expression of these cell apoptosis proteins. 
Effect of moxibustion treatment on oncogenes relating to cell proliferation
To explore the cell proliferation in gastric mucosa, we detected oncogenes relating to cell proliferation by using ELISA,
RT-PCR and western blotting. blockers or gene knockout technique should be used to prove molecular mechanism in the future.
In conclusion, this study provided evidence for that moxibustion treatment of ST21 and ST36 had a potent gastro-protective effect against gastric precancerous lesions, the underlying mechanism was involved in inhibiting the expression of bcl-2, P53, C-MYC and decreasing the activity of NF-κB as well as EGFR/ERK signaling proteins, indicated that moxibustion treatment might be beneficial in preventing against gastric carcinoma.
